van der Poel HG - Search Results

1

Timing of curative treatment for prostate cancer: a systematic review.

van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG. van den Bergh RC, et al. Among authors: van der poel hg. Eur Urol. 2013 Aug;64(2):204-15. doi: 10.1016/j.eururo.2013.02.024. Epub 2013 Feb 22. Eur Urol. 2013. PMID: 23453419 Free PMC article. Review.

2

Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer.

van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA. van der Poel HG, et al. Among authors: van stratum p. Urology. 1996 Sep;48(3):357-64. doi: 10.1016/S0090-4295(96)00210-5. Urology. 1996. PMID: 8804485 Free article. Clinical Trial.

3

Intratumoral nuclear morphologic heterogeneity in prostate cancer.

van der Poel HG, Oosterhof GO, Schaafsma HE, Debruyne FM, Schalken JA. van der Poel HG, et al. Urology. 1997 Apr;49(4):652-7. doi: 10.1016/s0090-4295(96)00557-2. Urology. 1997. PMID: 9111646 Free article.

4

Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer.

Van der Poel HG, Van Balken MR, Schamhart DH, Peelen P, de Reijke T, Debruyne FM, Schalken JA, Witjes JA. Van der Poel HG, et al. Among authors: van balken mr. Urology. 1998 Jan;51(1):44-50. doi: 10.1016/s0090-4295(97)00496-2. Urology. 1998. PMID: 9457287

5

Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.

van Rhijn BW, van der Poel HG, Boon ME, Debruyne FM, Schalken JA, Witjes JA. van Rhijn BW, et al. Among authors: van der poel hg. Urology. 2000 Mar;55(3):363-7. doi: 10.1016/s0090-4295(99)00460-4. Urology. 2000. PMID: 10699611

6

Consecutive quantitative cytology in bladder cancer.

van der Poel HG, van Rhijn BW, Peelen P, Debruyne FM, Boon ME, Schalken JA. van der Poel HG, et al. Among authors: van rhijn bw. Urology. 2000 Oct 1;56(4):584-8. doi: 10.1016/s0090-4295(00)00726-3. Urology. 2000. PMID: 11018610

7

Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer.

Sedelaar JP, van Leenders GJ, Hulsbergen-van de Kaa CA, van der Poel HG, van der Laak JA, Debruyne FM, Wijkstra H, de la Rosette JJ. Sedelaar JP, et al. Among authors: van leenders gj, van der laak ja, van der poel hg. Eur Urol. 2001 Sep;40(3):285-93. doi: 10.1159/000049788. Eur Urol. 2001. PMID: 11684844

8

Smart drugs in prostate cancer.

van der Poel HG. van der Poel HG. Eur Urol. 2004 Jan;45(1):1-17. doi: 10.1016/j.eururo.2003.08.011. Eur Urol. 2004. PMID: 14667509 Review.

9

Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.

van der Poel HG. van der Poel HG. J Urol. 2004 Oct;172(4 Pt 1):1333-7. doi: 10.1097/01.ju.0000138829.97838.19. J Urol. 2004. PMID: 15371835

10

Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience.

Kroon BK, Horenblas S, Meinhardt W, van der Poel HG, Bex A, van Tinteren H, Valdés Olmos RA, Nieweg OE. Kroon BK, et al. Among authors: van der poel hg, van tinteren h. Eur Urol. 2005 May;47(5):601-6; discussion 606. doi: 10.1016/j.eururo.2004.11.018. Epub 2005 Jan 22. Eur Urol. 2005. PMID: 15826750

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

515 results

Search Page

Filters